Urinary Clusterin identified as Biomarker for Kidney Disease Progression and Response to the Endothelin Receptor Antagonist Atrasentan
PRIME-CKD aims to identify, validate and implement biomarkers for kidney disease progression and thus improve the treatment response of individual patients to drugs that enhance kidney outcomes into clinical practice.In a recent paper in Nature Communications PRIME-CKD researchers have clearly shown that urinary Clusterin is associated with kidney disease progression and response to atrasentan treatment, supporting its potential as a pharmacodynamic biomarker to target therapy.
Dr. Wenjun Ju (University of Michigan) says: “With this study we have further supported the potential of urinary Clusterin as an important biomarker that can inform [WJ1] us better about the kidney disease progression of individual patients and how they respond to atrasentan, a drug currently in development for the treatment of IgA nephropathy. The credit for these results goes to the entire BEAt-DKD and PRIME-CKD consortia, associates, and stakeholders for years of hard work and support!”